MX2021005462A - Lipidos cationicos que contienen silicio. - Google Patents

Lipidos cationicos que contienen silicio.

Info

Publication number
MX2021005462A
MX2021005462A MX2021005462A MX2021005462A MX2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A MX 2021005462 A MX2021005462 A MX 2021005462A
Authority
MX
Mexico
Prior art keywords
containing silicon
cationic lipids
lipids containing
methods
lipid
Prior art date
Application number
MX2021005462A
Other languages
English (en)
Inventor
James Heyes
Mark Wood
Richard J Holland
Michael J Abrams
Kieu Mong Lam
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of MX2021005462A publication Critical patent/MX2021005462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1888—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of other Si-linkages, e.g. Si-N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Determinadas modalidades de la invención proporcionan un lípido catiónico de la fórmula (I) (ver formula) en donde R1, R2, R3 y R4 se definen como se describe en este documento, así como los métodos para preparar estos lípidos. Determinadas modalidades de la invención también proporcionan partículas lipídicas de ácido nucleico que comprenden un lípido catiónico de la fórmula (I), métodos para preparar las partículas lipídicas y métodos para proporcionar y/o administrar las partículas lipídicas.
MX2021005462A 2018-11-09 2019-11-08 Lipidos cationicos que contienen silicio. MX2021005462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758108P 2018-11-09 2018-11-09
PCT/US2019/060556 WO2020097520A1 (en) 2018-11-09 2019-11-08 Cationic lipids containing silicon

Publications (1)

Publication Number Publication Date
MX2021005462A true MX2021005462A (es) 2021-08-24

Family

ID=70612265

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005462A MX2021005462A (es) 2018-11-09 2019-11-08 Lipidos cationicos que contienen silicio.

Country Status (13)

Country Link
US (1) US20220133636A1 (es)
EP (1) EP3877001A4 (es)
JP (1) JP2022501064A (es)
KR (1) KR20210105888A (es)
CN (1) CN113286622A (es)
AU (1) AU2019376006A1 (es)
BR (1) BR112021008953A2 (es)
CA (1) CA3119051A1 (es)
EA (1) EA202191315A1 (es)
IL (1) IL282957A (es)
MX (1) MX2021005462A (es)
SG (1) SG11202104682PA (es)
WO (1) WO2020097520A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006539A2 (pt) 2018-10-09 2021-07-06 Univ British Columbia composições e sistemas competentes de vesículas competentes para transfecção isentas de solventes e detergentes orgânicos e métodos relacionados às mesmas
AU2020355000A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
EP4041894A1 (en) 2019-09-23 2022-08-17 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
AU2021234302A1 (en) 2020-03-11 2022-11-10 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
AU2009303345B2 (en) * 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
US9028603B2 (en) * 2011-06-09 2015-05-12 The Research Foundation Of State University Of New York Anti-fouling coating compositions and methods for preventing the fouling of surfaces
JP6590802B2 (ja) * 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 化学療法用薬剤、核酸及び光増感剤の送達又は共送達のためのナノスケール輸送体
CN106834355B (zh) * 2015-12-07 2021-02-23 北京大学 一种阳离子复合脂质纳米盘及其制备方法和用途
EP3269785A1 (de) * 2016-07-13 2018-01-17 Nitrochemie Aschau GmbH Zusammensetzung für silikonkautschukmassen
WO2018119115A1 (en) * 2016-12-21 2018-06-28 Protiva Biotherapeutics, Inc. Methods for ameliorating infusion reactions
WO2019051257A2 (en) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation METHODS OF TREATING HEPATITIS B TYPE INFECTIONS
US20220168222A1 (en) * 2019-04-26 2022-06-02 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
BR112021008953A2 (pt) 2021-08-10
CA3119051A1 (en) 2020-05-14
US20220133636A1 (en) 2022-05-05
KR20210105888A (ko) 2021-08-27
JP2022501064A (ja) 2022-01-06
EA202191315A1 (ru) 2021-09-08
EP3877001A1 (en) 2021-09-15
SG11202104682PA (en) 2021-06-29
AU2019376006A1 (en) 2021-06-03
IL282957A (en) 2021-06-30
CN113286622A (zh) 2021-08-20
WO2020097520A1 (en) 2020-05-14
EP3877001A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
MX2021005462A (es) Lipidos cationicos que contienen silicio.
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HK1103391A1 (en) Cationic lipids and methods of use
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MY194902A (en) Pyrimidine compound
SA516380290B1 (ar) نواقل لفيروس مرتبط بالغدد لعلاج اضطرابات الاختزان في الجسيمات الحالة
EA201691448A1 (ru) Гибридосомы, содержащие их композиции, способы их получения и их применения
MA47664B1 (fr) Anticorps anti-c10orf54 et leurs utilisations
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MY184586A (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
MX2019010340A (es) Formulacion mejorada de lipido.
NO20090596L (no) Antivirale fosfinatforbindelser
AU2018277520A1 (en) 6-5 fused rings as C5a inhibitors
NZ737322A (en) Notch pathway signaling inhibitor compounds
PH12019500196A1 (en) Compounds and compositions and uses thereof
MX2018015236A (es) Lipido cationico.
MX2019014292A (es) Anillos 5-5 fusionados como inhibidores c5a.
PH12020551486A1 (en) Cyclopentane-based modulators of sting (stimulator of interferon genes)
BR112019004911A2 (pt) oligonucleotídeos modificados e métodos de uso
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
JOP20210305A1 (ar) صيغ إيماتينيب وتصنيعها واستخداماتها
MX2017002775A (es) Derivados de pirrolopirimidina como antagonistas del receptor de n-metil-d-aspartato (nmda), subunidad nr2b.
MX2020000523A (es) Compuestos de isocromano y usos de los mismos.
MX2017015370A (es) Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b.
PH12019501893A1 (en) Methods for increasing blood plasma 2`-deoxyuridine (durd) and thymidylate synthase inhibition